COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases

INTRODUCTION: Patients with immune-mediated glomerular diseases are considered at high risk for severe COVID-19 outcomes. However, conclusive evidence for this patient population is scarce. METHODS: We created a global registry and retrospectively collected clinical data of patients with COVID-19 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Gauckler, Philipp, Kesenheimer, Jana S., Geetha, Duvuru, Odler, Balazs, Eller, Kathrin, Laboux, Timothee, Alberici, Federico, Zappa, Mattia, Chebotareva, Natasha, Moiseev, Sergey, Bonilla, Marco, Jhaveri, Kenar D., Oniszczuk, Julie, Audard, Vincent, Costa, Denise, Mastroianni-Kirsztajn, Gianna, Bruchfeld, Annette, Muto, Masahiro, Windpessl, Martin, Mayer, Gert, Kronbichler, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520971/
https://www.ncbi.nlm.nih.gov/pubmed/37767096
http://dx.doi.org/10.3389/fimmu.2023.1228457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520971/
https://www.ncbi.nlm.nih.gov/pubmed/37767096
http://dx.doi.org/10.3389/fimmu.2023.1228457

Ejemplares similares